AMO-04 Q&A

What is AMO-04?
AMO-04 is a repurposed drug, also called tianeptine, that has been approved for other indications such as depression, Parkinson's disease, post-traumatic brain disorder, and asthma. It's mechanism of action affects the glutamate biological pathway in the brain.

What symptoms is AMO-04 trying to alleviate?
Breathing irregularities. In mice, AMO-04 (previously called REV-003) was well-tolerated, improved motor coordination and gait, improved visual function, reduced other behavioral and neurological tests conducted and had no effects on body weight, http://www.marketwired.com/press-release/revive-therapeutics-ltd-announces-positive-study-results-in-rett-syndrometsx-venture-rvv-2180920.htm

When will the trial actually start?
AMO has not announced a timeline for the clinical trial.

What phase will the trial be in and what does that mean?
This may be a Phase 2 clinical in Rett syndrome, because this is a repurposed drug already approved for treatment of other indications.

When can we expect to know trial enrollment dates?
AMO has not announced a timeline for the clinical trial.

Are there any known patient criteria for participation?
AMO has not announced any details about the design of the clinical trial.

Have there been any locations selected for this trial?
AMO has not announced any details about the design of the clinical trial. No sites have been identified at this time, but it is most likely that this trial will be in Europe initially.

What does Orphan Drug Designation mean?
Please read our blog: https://www.rettsyndrome.org/research/research-videos-blogs/neuren-orphan-drug-status

What does glutamate do in the human body?
Glutamate is an important neurotransmitter required for brain development, maintenance and function. It affects neuroplasticity and synapses as well as brain cell growth.